Class summary at a glance.

Every drug in the Angiotensin 2 Receptor Blocker class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 11tracked in Part D
CY24 Part D spend: $561.9Mcombined across class
Total Rx claims: 19.4M6.3M unique beneficiaries
Generic mfrs (active): 104across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Valsartan

Brand: Diovan · 7.3M Part D claims (CY24) · 2.4M beneficiaries · First FDA approval: 2001-07-01

17 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.102

→

Avg plan cost$0.650

Part D spend $228.8M 6× spread, current vs floor

Class share

41%

of class CY24 spend

View profile →

Olmesartan Medoxomil

Brand: Benicar · 5.4M Part D claims (CY24) · 1.8M beneficiaries · First FDA approval: 2016-04-01

19 generic mfrs 0 plans require PA

Low NADAC$0.058

→

Avg plan cost$0.843

Part D spend $127.5M 15× spread, current vs floor

Class share

23%

of class CY24 spend

View profile →

Irbesartan

Brand: Avapro · 3.9M Part D claims (CY24) · 1.2M beneficiaries · First FDA approval: 2012-09-27

15 generic mfrs 0 plans require PA

Low NADAC$0.084

→

Avg plan cost$0.418

Part D spend $84.3M 5× spread, current vs floor

Class share

15%

of class CY24 spend

View profile →

Candesartan Cilexetil

Brand: ATACAND · 759K Part D claims (CY24) · 234K beneficiaries · First FDA approval: 1998-06-04

5 generic mfrs 0 plans require PA

Low NADAC$0.495

→

Avg plan cost$2.14

Part D spend $61.4M 4× spread, current vs floor

Class share

11%

of class CY24 spend

View profile →

Telmisartan

Brand: Micardis · 2.0M Part D claims (CY24) · 667K beneficiaries · First FDA approval: 2000-12-01

16 generic mfrs 0 plans require PA

Low NADAC$0.104

→

Avg plan cost$0.290

Part D spend $59.8M 3× spread, current vs floor

Class share

11%

of class CY24 spend

View profile →

Amlodipine and Valsartan

Brand: Exforge · — Part D claims (CY24) · First FDA approval: 2007-06-20

8 generic mfrs 0 plans require PA

Low NADAC$0.439

→

Avg plan cost$1.27

Part D spend — 3× spread, current vs floor

Class share

of class CY24 spend

View profile →

Irbesartan and Hydrochlorothiazide

Brand: Avalide · — Part D claims (CY24) · First FDA approval: 2012-09-27

9 generic mfrs 0 plans require PA

Low NADAC$0.153

→

Avg plan cost$0.691

Part D spend — 5× spread, current vs floor

Class share

of class CY24 spend

View profile →

Sacubitril and Valsartan

Brand: ENTRESTO · — Part D claims (CY24) · First FDA approval: 2015-07-07

14 generic mfrs 6 plans require PA

Low NADAC$0.596

→

Avg plan cost$1.49

Part D spend — 3× spread, current vs floor

Class share

of class CY24 spend

View profile →

Telmisartan and Amlodipine

— Part D claims (CY24) · First FDA approval: 2014-01-08

1 generic mfrs 0 plans require PA

Low NADAC$2.49

→

Avg plan cost$2.73

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Telmisartan, Amlodipine and Indapamide

Brand: WIDAPLIK · — Part D claims (CY24) · First FDA approval: 2025-10-20

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Valsartan Oral

Brand: Valsartan · — Part D claims (CY24) · First FDA approval: 2025-06-05

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.